Ohio Senate GOP moves to give wealthiest Ohioans tax cut
Ohio Republican senators have proposed a flat income tax for the state's top earners, which would result in a projected $1 billion loss in the general revenue fund.
Bailey Williams is like the average Ohioan — earning less than six figures a year. According to census data, the median income in the state is about $68,000. He's worried about the Senate's newly proposed state budget.
'The services that made me who I am today, public education made me who I am today. I worry about those opportunities being there for my younger siblings,' Williams said.
He is also a researcher with the nonpartisan organization Policy Matters Ohio and is evaluating a budget provision — one that creates a flat income tax of 2.75%.
There are three income tax brackets in Ohio. Those making up to $26,000 do not need to pay state income tax. Ohioans earning between $26,000 and $100,000 pay a tax of 2.75%. Those making more than $100,000 have to pay 3.5%.
Senate President Rob McColley (R-Napoleon) said that the highest earners in the state will have their income tax payment reduced to 2.75%.
'Every tax cut we do in the future will involve every single person equally, on a percentage basis,' McColley said.
State data reveals that this could result in a loss of about $1.1 billion in the General Revenue Fund.
How would Ohio make up the deficit from the tax?
'One of two ways,' Williams said. 'We're going to see increases in regressive taxes, most likely the sales tax, or we have to make do with less — less government services.'
Many cuts for programs that benefit lower-income families have already been proposed in the budget. Funding for schools, Medicaid, libraries, lead abatement, food banks and child care face funding decreases from the current status or from the governor's budget.
When McColley was asked how he defends cuts to Medicaid, lead poisoning prevention and child care while allowing a lower tax rate for wealthier Ohioans, he said the 'growth in Medicaid spending has been exponential.'
According to the Legislative Service Commission, a nonpartisan agency that works with the legislature, the proposed budget would result in a 4% decrease in spending, with billions of dollars in cuts.
He said that there was already an 'awful lot' of lead program funding and said that they were keeping child care the same as before. However, the budget would cut the governor's proposal of offering Publicly Funded Child Care to families earning up to 160% of the federal poverty level, keeping it at the current 145% threshold.
'No multimillionaire needs a $10,000 tax cut bankrolled by cutting lead abatement or Medicaid,' Williams said.
McColley said the elimination of 11% of the state's income tax revenue would not actually impact funding because he predicts companies will move to Ohio to take advantage of that lower tax rate.
'A lower tax burden has had a positive economic development and brought more jobs to the state,' McColley said. 'It's brought more investment in the state.'
The budget will continue to be heard, and a final version will need to be agreed upon by the Senate and House by the end of June.
Click here to learn more about the House's passed budget.
Follow WEWS statehouse reporter Morgan Trau on Twitter and Facebook.
SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
SUPPORT: YOU MAKE OUR WORK POSSIBLE
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Los Angeles Times
21 minutes ago
- Los Angeles Times
Trump tax law could cause Medicare cuts if Congress doesn't act, CBO says
WASHINGTON — The federal budget deficits caused by President Trump's tax and spending law could trigger automatic cuts to Medicare if Congress does not act, the nonpartisan Congressional Budget Office reported Friday. The CBO estimates that Medicare, the federal health insurance program for Americans over age 65, could potentially see as much as $491 billion in cuts from 2027 to 2034 if Congress does not act to mitigate a 2010 law that forces across-the-board cuts to many federal programs once legislation increases the federal deficit. The latest report from CBO showed how Trump's signature tax and spending law could put new pressure on federal programs that are bedrocks of the American social safety net. Trump and Republicans pledged not to cut Medicare as part of the legislation, but the estimated $3.4 trillion that the law adds to the federal deficit over the next decade means that many Medicare programs could see cuts. In the past, Congress has always acted to mitigate cuts to Medicare and other programs, but it would take some bipartisan cooperation to do so. Democrats, who requested the analysis from CBO, jumped on the potential cuts. 'Republicans knew their tax breaks for billionaires would force over half a trillion dollars in Medicare cuts — and they did it anyway,' Rep. Brendan Boyle of Pennsylvania, the top Democrat on the House Budget Committee, said in a statement. 'American families simply cannot afford Donald Trump's attacks on Medicare, Medicaid and Obamacare.' Hospitals in rural parts of the country are already grappling with cuts to Medicaid, which is available to people with low incomes, and cuts to Medicare could exacerbate their shortfalls. As Republicans muscled the bill through Congress and are now selling it to voters back home, they have been critical of how the CBO has analyzed the bill. They have also argued that the tax cuts will spur economic growth and pointed to $50 billion in funding for rural hospitals that was included in the package. Groves writes for the Associated Press.
Yahoo
2 hours ago
- Yahoo
Merck KGaA ventures into new territory in the US
This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Merck KGaA has been making new moves to propel itself into becoming what CEO Belén Garijo described as a 'globally diversified science and technology powerhouse.' Most recently, the company closed its $3.4 billion acquisition of Pfizer spinout SpringWorks Therapeutics, which will help it stake a claim in the rare tumor space. And in general, it's all about 'doubling down' on R&D and building the company's U.S. footprint, said Miguel Fernández Alcalde, president of EMD Serono, Merck KGaA's healthcare business in the U.S. and Canada. Germany-based Merck KGaA has undergone a number of transformations throughout its deep history. In 2022, the company restructured into three distinct business units including one focused on the life sciences sector and manufacturing services. But with the contract manufacturing blitz of the COVID-19 pandemic era fading, the company is refocusing. EMD Serono relocated its U.S. headquarters to Boston's Seaport district to place itself squarely in the thick of the region's most innovative 'biotechs, startups, academia and scientists,' Fernández Alcalde said. 'I want to make sure we are bringing the U.S. [business] to the next level in terms of contributions to the whole organization." Miguel Fernández Alcalde President, EMD Serono Merck KGaA also elevated its global head of R&D and chief medical officer of its healthcare business, Dr. Danny Bar-Zohar, to healthcare CEO. 'That tells you that the company's moving along in the direction of doubling down on R&D,' Fernández Alcalde said. Fernández Alcalde's appointment to president of EMD Serono in December is also part of the company's overall quest to build its U.S. footprint and bolster R&D through external deals. 'I want to make sure we are bringing the U.S. [business] to the next level in terms of contributions to the whole organization,' he said. 'I do think we have lots of opportunities in the U.S. ecosystem and U.S. market. My job and my vision and ambition is to really untap all those things that we have ahead of us.' A pharmacist by trade, Fernández Alcalde has been with Merck KGaA since 2014, serving most recently as EMD Serono's chief operating officer. 'That gave me a lot of knowledge and understanding of the business of the company in the States and the teams, the dynamics, the culture, but also the U.S. [healthcare] ecosystem,' he said. Driving dealmaking Central to Fernández Alcalde's role is supplementing the company's current pipeline through external innovation investments, including more strategic in-licensing and co-development opportunities. The SpringWorks acquisition put the company on track to generate at least 50% of its future launch assets from external companies, compared to roughly 10%-15% just 18 months ago. 'It's easily a fivefold increase in our ambition from external innovation,' Fernández Alcalde said. In terms of what kinds of deals they're targeting, Fernández Alcalde said several factors are at play. 'We are not looking [for] the $40 billion type of acquisition,' he said. Nor will they chase first-in-class potential blockbusters with never-explored mechanisms of action. Instead, they'll target smaller deals with the 'right risk balance' for their pipeline. He pointed to the SpringWorks acquisition as an example, which not only adds two FDA-approved drugs to its portfolio, but also a 'runway of three to five years of nice growth' in the form of several clinical-phase pipeline candidates. 'These areas where we have deep, good science [and a] validated proof of concept or an about-to-be-validated proof of concept where the mechanism of action is already validated, is something we are interested in,' he said. The company will take a similar approach when it comes to therapeutic areas by branching out within reason. 'We are not sticking to the [therapeutic areas] we have today, but we are not going to go wild, either,' he said. Rather, they'll look for specialties that are 'adjacent' and 'logical' in terms of what they've been historically known for, such as oncology and neurology/immunology. Again, he pointed to the SpringWorks acquisition as an example and noted that some might ask what track record EMD Serono or Merck KGaA has in rare tumors. 'The answer is zero. But we do know how to commercialize,' he said. Plus, 'it's in an adjacent area of oncology.' Fernández Alcalde is also thinking globally, intending to follow good science wherever it leads and consider deals from around the world. 'We couldn't care less about where that science is coming from, whether it's China, my home country Spain, the U.S. or South Africa,' he said. 'If we think that science will help patients … we will definitely think about it.' Recommended Reading Let's make a deal? Big Pharma execs express varying views on their M&A future
Fox News
5 hours ago
- Fox News
'The Obama Legacy is In Trouble': Julian Epstein, former Democrat, Weighs in on Obama's Mamdani Call
Julian Epstein, attorney, former chief counsel to the Democratic House Judiciary Committee, and NYP Columnist, joined the Guy Benson Show with guest host Harry Hurley today to discuss the lost state of the Democratic party. The pair weighed in on the radicalism of Zohran Mamdani and why the 'Obama brand' suffers from his reported phone call with the radical. Epstein also weighed in on the 'weak' state of Democratic leadership in the House and in the Senate, and you can listen to the full interview below! Listen to the full interview below: Listen to the full podcast below:
